ArticleFrontiers in oncology2026
Glioblastoma in adults with prior extracranial cancer: a Czech retrospective multicentre study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with a history of extracranial cancers (EXCA) who develop new intracranial lesions are commonly presumed to harbour brain metastases, yet primary glioblastoma (GBM) can also arise Methods: We retrospectively analysed adult patients with concurrent prior solid EXCA and supratentorial GBM treated at three Czech neuro-oncology centres between January 2010 and December 2022. Patients with hematologic malignancies or needle-biopsy-only diagnoses were excluded. Demographic, clinical, molecular (IDH, MGMT), surgical (RANO RESECT 2022 extent-of-resection classification), and treatment data were collected and related to progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier estimation, log-rank tests, and Cox regression. Results: Of 1,182 patients operated for GBM, 48 (4.0%) had a documented prior solid EXCA. Median age at EXCA diagnosis was 57.5 years (range 21-82); median age at GBM diagnosis was 65 years (range 46-82). The median interval between diagnoses was 5.7 years (range 0.1-27.3). All 48 GBMs were IDH-wildtype; MGMT promoter status was assessable in 23 cases (17 unmethylated, 6 methylated), of which 22 had follow-up data available for survival analysis. Median PFS was 8.4 months (95% CI 7.6-27.3) and median OS was 10.6 months (95% CI 5.7-16.8). MGMT methylation (mOS 29.3 vs 12.0 months; p = 0.037), higher Karnofsky score, more radical surgical resection, and completion of the Stupp protocol (mOS 19.2 vs 2.5 months for no oncotherapy; p = 0.019) were each significantly associated with longer OS. Conclusions: A new brain lesion in a cancer survivor must not be assumed to be metastatic without histological confirmation. When patients with GBM after prior EXCA are eligible for standard radical surgery and Stupp-protocol oncotherapy, survival outcomes are comparable to those reported for sporadic GBM. Standard treatment protocols are appropriate for this population; a history of extracranial cancer is not in itself an adverse prognostic factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.